A recent large Parkinson's Disease (PD) twin study indicates that environmental and toxic factors play major roles in causing typical PD (Tanner, et. al. JAMA, 1999). Interestingly, neuroinflammation seen in the caudate-putamen is a part of the pathophysiology (Brooks, 1999). The progressive decline of dopamine (DA) terminals seen in idiopathic PD can be closely modeled in Macaca fascicularis by low-dose exposure to the mitochondrial toxin, MPTP, over nine to fourteen months. The investigators demonstrated by PET imaging of DA terminal and MRS that such primates provide a physiological chart of degeneration and appearance of PD signs (Brownell, et. al., Nat. Med., 1998). This data profile enables the design of an experimental paradigm for realistically determining toxicity, neuroinflammation and neuroprotection in idiopathic PD. In this project using the PD primate model, the investigators now propose to examine neuroprotection of the dopaminergic system by anti-inflammatory agents. Based on several studies, they hypothesize that a cyclooxygenase (COX) 1 and 2 inhibitor (indomethacin [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid]) can decrease inflammatory reactions caused by MPP+ toxicity and also reduce chronic neurodegenerative processes. In the non-human primate, a slow progressive lesion of the nigrostriatal dopaminergic system follows repeated MPTP treatment. Using PET scanning with a receptor ligand for the peripheral benzodiazepine receptor site (11-C-PK1 1195), preliminary experiments indicate that they can visualize the neuroinflammatory reactions during CNS DA degeneration (as determined by 11-C-CFT). These measurements will be combined with MRI and MRS studies of lactate and choline as in vivo biomarkers for the glial inflammatory and toxic responses of the nigrostriatal system. As a therapy, during and after neurotoxic exposure to MPTP, the investigators will treat the PD primates with a COX I and 2 inhibitor to evaluate anti- inflammatory prevention of onset and continued degeneration. Protection of the dopaminergic system by anti-inflammatory agents would be of tremendous therapeutic value for PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS041263-01
Application #
6215952
Study Section
Special Emphasis Panel (ZES1-LKB-C (D1))
Program Officer
Oliver, Eugene J
Project Start
2000-09-30
Project End
2005-08-31
Budget Start
2000-09-30
Budget End
2001-08-31
Support Year
1
Fiscal Year
2000
Total Cost
$481,114
Indirect Cost
Name
Mc Lean Hospital (Belmont, MA)
Department
Type
DUNS #
City
Belmont
State
MA
Country
United States
Zip Code
02478
Sanchez-Pernaute, Rosario; Brownell, Anna-Liisa; Jenkins, Bruce G et al. (2005) Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging. Toxicol Appl Pharmacol 207:251-6
Isacson, Ole; Bjorklund, Lars M; Schumacher, James M (2003) Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol 53 Suppl 3:S135-46; discussion S146-8
McNaught, Kevin St P; Belizaire, Roger; Isacson, Ole et al. (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179:38-46
Sanchez-Pernaute, R; Brownell, A L; Isacson, O (2002) Functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration. Neurotoxicology 23:469-78
Cicchetti, F; Brownell, A L; Williams, K et al. (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991-8
Isacson, Ole (2002) Models of repair mechanisms for future treatment modalities of Parkinson's disease. Brain Res Bull 57:839-46
McNaught, Kevin St P; Belizaire, Roger; Jenner, Peter et al. (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 326:155-8
Bjorklund, Lars M; Isacson, Ole (2002) Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease. Prog Brain Res 138:411-20